NDAQ:ISEE - Post Discussion
Post by
AviseAnalytics on Jul 06, 2022 7:56am
UPCOMING CATALYST MAKES IVERIC BIO A MUST WATCH!
$ISEE
Iveric Bio, Inc. (NASDAQ: ISEE), is a clinical-stage biopharmaceutical company developing transformative therapies for retinal diseases with significant unmet needs.
The Company’s lead product candidate is Zimura (avacincaptad pegol), a C5 inhibitor that is currently being evaluated in a Phase 3 trial, the topline results from which are expected to be announced in Q3,2022.
https://www.aviseanalytics.com/upcoming-catalyst-makes-iveric-bio-a-must-watch/
Be the first to comment on this post